Lyme Disease Treatment Market By Treatment (Medication, Tick Removal), By Administration Route (Oral, Injectable, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global Lyme disease treatment market is envisioned to garner $1,636.6 million by 2031, growing from $737.5 million in 2021 at a CAGR of 8.4% from 2022 to 2031.
Chronic Lyme disease is the most frequent kind of tick-borne or vector-borne disease. Lyme disease, also known as Lyme borreliosis, is caused by the bite of a tick infected with the bacteria Borrelia burgdorferi. Early Lyme disease symptoms include circular rashes around the place of the tick bite, fever, nausea, and headache. If Lyme disease is not discovered early, the chronic Lyme disease infection may spread to other organs such as joints and muscles. Many oral treatments for Lyme disease are available in the market, including doxycycline, amoxicillin, and cefuroxime.
Lyme disease is sometimes misunderstood in people as a typical rash or a seasonal allergy because patients with Lyme disease exhibit similar symptoms such as fever and body aching. This aspect is anticipated to stymie the expansion of the Lyme disease treatment market in the approaching years. In addition, a lack of public understanding regarding the prevalence and symptoms of Lyme disease is expected to hamper the market growth.
Antibiotics have been determined to be the most effective therapy for Lyme disease. Patients in the early stages of Lyme disease recover quickly and completely with antibiotics such as doxycycline, amoxicillin, and cefuroxime axetil. Intravenous ceftriaxone may be administered to patients suffering from certain neurological or cardiac illnesses. Patients who have had persistent Lyme disease symptoms for more than 6 months can recover in a few weeks with oral antibiotic therapy.
The coronavirus pandemic has break off all medical and healthcare sectors to the diagnosis and treatment of COVID-19 patients. This has had an influence on various sectors of health and therapy, including the Lyme disease treatment industry. Outpatient visits to healthcare providers have been limited due to a patient's fear about contamination. Indicative patients may be thought to have COVID-19 until negative test results are obtained, implying that examinations for other therapies may be postponed, perhaps leading to poor consequences. Individuals with Lyme disease symptoms were urged to postpone their testing while the coronavirus spread over the world. People were urged to be quarantined since screening for alternative reasons of the patient's symptoms other than COVID-19 was frequently delayed, causing delayed treatments and consequences.
The key players profiled in this report include GSK plc., Pfizer, Inc., Novartis AG, Mayne Pharma Group Limited, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Orion Corporation, Perrigo Company plc., ChartwellPharma, and Almirall, LLC.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lyme disease treatment market analysis from 2021 to 2031 to identify the prevailing lyme disease treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the lyme disease treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global lyme disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Administration Route
Oral
Injectable
Topical
By Treatment
Medication
Tick Removal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
United Kingdom
France
Russia
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Singapore
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
UAE
South Africa
Rest of LAMEA
Key Market Players
Galaxo SmithKline Plc
Pfizer, Inc.
Novartis AG
Mayne Pharma
Sun Pharmaceuticals Industries, Inc
Lupin Pharmaceuticals, Inc.
Orion Corporation
Perrigo Company plc
Chartwell Pharmaceuticals
Almirall, LLC
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Value Chain Analysis
- 3.8.Regulatory Guidelines
- 3.9.Market Share Analysis
- 3.10.Key Regulation Analysis
- 3.11.Patent Landscape
- CHAPTER 4: LYME DISEASE TREATMENT MARKET, BY TREATMENT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Medication
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Tick Removal
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oral
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Injectable
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Topical
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Online
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: LYME DISEASE TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Treatment
- 7.2.3 North America Market size and forecast, by Administration Route
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Treatment
- 7.2.5.1.2 Market size and forecast, by Administration Route
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Treatment
- 7.2.5.2.2 Market size and forecast, by Administration Route
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Treatment
- 7.2.5.3.2 Market size and forecast, by Administration Route
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Treatment
- 7.3.3 Europe Market size and forecast, by Administration Route
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Treatment
- 7.3.5.1.2 Market size and forecast, by Administration Route
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 United Kingdom
- 7.3.5.2.1 Market size and forecast, by Treatment
- 7.3.5.2.2 Market size and forecast, by Administration Route
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 France
- 7.3.5.3.1 Market size and forecast, by Treatment
- 7.3.5.3.2 Market size and forecast, by Administration Route
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Russia
- 7.3.5.4.1 Market size and forecast, by Treatment
- 7.3.5.4.2 Market size and forecast, by Administration Route
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Italy
- 7.3.5.5.1 Market size and forecast, by Treatment
- 7.3.5.5.2 Market size and forecast, by Administration Route
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Treatment
- 7.3.5.6.2 Market size and forecast, by Administration Route
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Treatment
- 7.4.3 Asia-Pacific Market size and forecast, by Administration Route
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Treatment
- 7.4.5.1.2 Market size and forecast, by Administration Route
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Treatment
- 7.4.5.2.2 Market size and forecast, by Administration Route
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Treatment
- 7.4.5.3.2 Market size and forecast, by Administration Route
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 South Korea
- 7.4.5.4.1 Market size and forecast, by Treatment
- 7.4.5.4.2 Market size and forecast, by Administration Route
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 Singapore
- 7.4.5.5.1 Market size and forecast, by Treatment
- 7.4.5.5.2 Market size and forecast, by Administration Route
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Treatment
- 7.4.5.6.2 Market size and forecast, by Administration Route
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Treatment
- 7.5.3 LAMEA Market size and forecast, by Administration Route
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Treatment
- 7.5.5.1.2 Market size and forecast, by Administration Route
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Treatment
- 7.5.5.2.2 Market size and forecast, by Administration Route
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 UAE
- 7.5.5.3.1 Market size and forecast, by Treatment
- 7.5.5.3.2 Market size and forecast, by Administration Route
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 South Africa
- 7.5.5.4.1 Market size and forecast, by Treatment
- 7.5.5.4.2 Market size and forecast, by Administration Route
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- 7.5.5.5 Rest of LAMEA
- 7.5.5.5.1 Market size and forecast, by Treatment
- 7.5.5.5.2 Market size and forecast, by Administration Route
- 7.5.5.5.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Galaxo SmithKline Plc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Pfizer, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Novartis AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Mayne Pharma
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Sun Pharmaceuticals Industries, Inc
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Lupin Pharmaceuticals, Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Orion Corporation
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Perrigo Company plc
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Chartwell Pharmaceuticals
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Almirall, LLC
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 2. LYME DISEASE TREATMENT MARKET REVENUE, FOR MEDICATION, BY REGION , 2021-2031,($MILLION)
- TABLE 3. LYME DISEASE TREATMENT MARKET FOR MEDICATION BY COUNTRY, 2021-2031,($MILLION)
- TABLE 4. LYME DISEASE TREATMENT MARKET REVENUE, FOR TICK REMOVAL, BY REGION , 2021-2031,($MILLION)
- TABLE 5. LYME DISEASE TREATMENT MARKET FOR TICK REMOVAL BY COUNTRY, 2021-2031,($MILLION)
- TABLE 6. GLOBAL LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 7. LYME DISEASE TREATMENT MARKET REVENUE, FOR ORAL, BY REGION , 2021-2031,($MILLION)
- TABLE 8. LYME DISEASE TREATMENT MARKET FOR ORAL BY COUNTRY, 2021-2031,($MILLION)
- TABLE 9. LYME DISEASE TREATMENT MARKET REVENUE, FOR INJECTABLE, BY REGION , 2021-2031,($MILLION)
- TABLE 10. LYME DISEASE TREATMENT MARKET FOR INJECTABLE BY COUNTRY, 2021-2031,($MILLION)
- TABLE 11. LYME DISEASE TREATMENT MARKET REVENUE, FOR TOPICAL, BY REGION , 2021-2031,($MILLION)
- TABLE 12. LYME DISEASE TREATMENT MARKET FOR TOPICAL BY COUNTRY, 2021-2031,($MILLION)
- TABLE 13. GLOBAL LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 14. LYME DISEASE TREATMENT MARKET REVENUE, FOR HOSPITAL PHARMACIES, BY REGION , 2021-2031,($MILLION)
- TABLE 15. LYME DISEASE TREATMENT MARKET FOR HOSPITAL PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
- TABLE 16. LYME DISEASE TREATMENT MARKET REVENUE, FOR RETAIL PHARMACIES, BY REGION , 2021-2031,($MILLION)
- TABLE 17. LYME DISEASE TREATMENT MARKET FOR RETAIL PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
- TABLE 18. LYME DISEASE TREATMENT MARKET REVENUE, FOR ONLINE, BY REGION , 2021-2031,($MILLION)
- TABLE 19. LYME DISEASE TREATMENT MARKET FOR ONLINE BY COUNTRY, 2021-2031,($MILLION)
- TABLE 20. LYME DISEASE TREATMENT MARKET, BY REGION, 2021-2031,($MILLION)
- TABLE 21. NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 22. NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 23. NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 24. NORTH AMERICA LYME DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 25. U.S. LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 26. U.S. LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 27. U.S. LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 28. CANADA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 29. CANADA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 30. CANADA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 31. MEXICO LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 32. MEXICO LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 33. MEXICO LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 34. EUROPE LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 35. EUROPE LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 36. EUROPE LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 37. EUROPE LYME DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 38. GERMANY LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 39. GERMANY LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 40. GERMANY LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 41. UNITED KINGDOM LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 42. UNITED KINGDOM LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 43. UNITED KINGDOM LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 44. FRANCE LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 45. FRANCE LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 46. FRANCE LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 47. RUSSIA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 48. RUSSIA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 49. RUSSIA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 50. ITALY LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 51. ITALY LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 52. ITALY LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 53. REST OF EUROPE LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 54. REST OF EUROPE LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 55. REST OF EUROPE LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 56. ASIA-PACIFIC LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 57. ASIA-PACIFIC LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 58. ASIA-PACIFIC LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 59. ASIA-PACIFIC LYME DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 60. CHINA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 61. CHINA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 62. CHINA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 63. JAPAN LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 64. JAPAN LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 65. JAPAN LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 66. INDIA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 67. INDIA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 68. INDIA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 69. SOUTH KOREA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 70. SOUTH KOREA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 71. SOUTH KOREA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 72. SINGAPORE LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 73. SINGAPORE LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 74. SINGAPORE LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 75. REST OF ASIA-PACIFIC LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 76. REST OF ASIA-PACIFIC LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 77. REST OF ASIA-PACIFIC LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 78. LAMEA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 79. LAMEA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 80. LAMEA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 81. LAMEA LYME DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031,($MILLION)
- TABLE 82. BRAZIL LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 83. BRAZIL LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 84. BRAZIL LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 85. SAUDI ARABIA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 86. SAUDI ARABIA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 87. SAUDI ARABIA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 88. UAE LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 89. UAE LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 90. UAE LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 91. SOUTH AFRICA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 92. SOUTH AFRICA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 93. SOUTH AFRICA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 94. REST OF LAMEA LYME DISEASE TREATMENT MARKET, BY TREATMENT, 2021-2031,($MILLION)
- TABLE 95. REST OF LAMEA LYME DISEASE TREATMENT MARKET, BY ADMINISTRATION ROUTE, 2021-2031,($MILLION)
- TABLE 96. REST OF LAMEA LYME DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031,($MILLION)
- TABLE 97.GALAXO SMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 98.GALAXO SMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 99.GALAXO SMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 100.GALAXO SMITHKLINE PLC: NET SALES,
- TABLE 101.GALAXO SMITHKLINE PLC: KEY STRATERGIES
- TABLE 102.PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 103.PFIZER, INC.: OPERATING SEGMENTS
- TABLE 104.PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 105.PFIZER, INC.: NET SALES,
- TABLE 106.PFIZER, INC.: KEY STRATERGIES
- TABLE 107.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 108.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 109.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 110.NOVARTIS AG: NET SALES,
- TABLE 111.NOVARTIS AG: KEY STRATERGIES
- TABLE 112.MAYNE PHARMA: COMPANY SNAPSHOT
- TABLE 113.MAYNE PHARMA: OPERATING SEGMENTS
- TABLE 114.MAYNE PHARMA: PRODUCT PORTFOLIO
- TABLE 115.MAYNE PHARMA: NET SALES,
- TABLE 116.MAYNE PHARMA: KEY STRATERGIES
- TABLE 117.SUN PHARMACEUTICALS INDUSTRIES, INC: COMPANY SNAPSHOT
- TABLE 118.SUN PHARMACEUTICALS INDUSTRIES, INC: OPERATING SEGMENTS
- TABLE 119.SUN PHARMACEUTICALS INDUSTRIES, INC: PRODUCT PORTFOLIO
- TABLE 120.SUN PHARMACEUTICALS INDUSTRIES, INC: NET SALES,
- TABLE 121.SUN PHARMACEUTICALS INDUSTRIES, INC: KEY STRATERGIES
- TABLE 122.LUPIN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 123.LUPIN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 124.LUPIN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 125.LUPIN PHARMACEUTICALS, INC.: NET SALES,
- TABLE 126.LUPIN PHARMACEUTICALS, INC.: KEY STRATERGIES
- TABLE 127.ORION CORPORATION: COMPANY SNAPSHOT
- TABLE 128.ORION CORPORATION: OPERATING SEGMENTS
- TABLE 129.ORION CORPORATION: PRODUCT PORTFOLIO
- TABLE 130.ORION CORPORATION: NET SALES,
- TABLE 131.ORION CORPORATION: KEY STRATERGIES
- TABLE 132.PERRIGO COMPANY PLC: COMPANY SNAPSHOT
- TABLE 133.PERRIGO COMPANY PLC: OPERATING SEGMENTS
- TABLE 134.PERRIGO COMPANY PLC: PRODUCT PORTFOLIO
- TABLE 135.PERRIGO COMPANY PLC: NET SALES,
- TABLE 136.PERRIGO COMPANY PLC: KEY STRATERGIES
- TABLE 137.CHARTWELL PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 138.CHARTWELL PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 139.CHARTWELL PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 140.CHARTWELL PHARMACEUTICALS: NET SALES,
- TABLE 141.CHARTWELL PHARMACEUTICALS: KEY STRATERGIES
- TABLE 142.ALMIRALL, LLC: COMPANY SNAPSHOT
- TABLE 143.ALMIRALL, LLC: OPERATING SEGMENTS
- TABLE 144.ALMIRALL, LLC: PRODUCT PORTFOLIO
- TABLE 145.ALMIRALL, LLC: NET SALES,
- TABLE 146.ALMIRALL, LLC: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.LYME DISEASE TREATMENT MARKET SEGMENTATION
- FIGURE 2.LYME DISEASE TREATMENT MARKET,2021-2031
- FIGURE 3.LYME DISEASE TREATMENT MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.LYME DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.VALUE CHAIN ANALYSIS
- FIGURE 13.REGULATORY GUIDELINES
- FIGURE 14.MARKET SHARE ANALYSIS
- FIGURE 15.KEY REGULATION ANALYSIS
- FIGURE 16.PATENT ANALYSIS BY COMPANY
- FIGURE 17.PATENT ANALYSIS BY COUNTRY
- FIGURE 18.LYME DISEASE TREATMENT MARKET,BY TREATMENT,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MEDICATION LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF TICK REMOVAL LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 21.LYME DISEASE TREATMENT MARKET,BY ADMINISTRATION ROUTE,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ORAL LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INJECTABLE LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF TOPICAL LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 25.LYME DISEASE TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 28.COMPARATIVE SHARE ANALYSIS OF ONLINE LYME DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 29.LYME DISEASE TREATMENT MARKET BY REGION,2021
- FIGURE 30.U.S. LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 31.CANADA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 32.MEXICO LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 33.GERMANY LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 34.UNITED KINGDOM LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 35.FRANCE LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 36.RUSSIA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 37.ITALY LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 38.REST OF EUROPE LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 39.CHINA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 40.JAPAN LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 41.INDIA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 42.SOUTH KOREA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 43.SINGAPORE LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 44.REST OF ASIA-PACIFIC LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 45.BRAZIL LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 46.SAUDI ARABIA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 47.UAE LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 48.SOUTH AFRICA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 49.REST OF LAMEA LYME DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 53.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 54.COMPETITIVE DASHBOARD
- FIGURE 55.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 56.GALAXO SMITHKLINE PLC.: NET SALES ,($MILLION)
- FIGURE 57.PFIZER, INC..: NET SALES ,($MILLION)
- FIGURE 58.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 59.MAYNE PHARMA.: NET SALES ,($MILLION)
- FIGURE 60.SUN PHARMACEUTICALS INDUSTRIES, INC.: NET SALES ,($MILLION)
- FIGURE 61.LUPIN PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
- FIGURE 62.ORION CORPORATION.: NET SALES ,($MILLION)
- FIGURE 63.PERRIGO COMPANY PLC.: NET SALES ,($MILLION)
- FIGURE 64.CHARTWELL PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 65.ALMIRALL, LLC.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook